Simple MRI Measurement Could Avoid 30% of Breast Biopsies
Scientific findings are instantly applicable in clinical practice
March 9, 2021 Breast cancer is the most common fatal cancer in women. Early detection increases a woman s chances of recovery. Magnetic Resonance Imaging (MRI) is an accurate technique for detecting and classifying tumors in breast tissue. However, it sometimes causes false alarms , thus requiring further investigation (biopsy) and in some cases even resulting in so-called overtreatment, that is to say unnecessary surgery. For the first time, a research team from MedUni Vienna has now confirmed a threshold value for a non-invasive imaging biomarker. This can be incorporated into short standard MRI scans and could reduce the biopsy rate following MRI scans by 30%. Since the infrastructure for this measurement already exists in every radiological facility in Austria, the biomarker could be immediately deployed countrywide.
Researchers confirm a threshold value for non-invasive imaging biomarker
Breast cancer is the commonest fatal cancer in women. Early detection increases a woman s chances of recovery. Magnetic Resonance Imaging (MRI) is an accurate technique for detecting and classifying tumors in breast tissue.
However, it sometimes causes false alarms , thus requiring further investigation (biopsy) and in some cases even resulting in so-called overtreatment, that is to say, unnecessary surgery. For the first time, a research team from MedUni Vienna has now confirmed a threshold value for a non-invasive imaging biomarker.
This can be incorporated into short standard MRI scans and could reduce the biopsy rate following MRI scans by 30%. Since the infrastructure for this measurement already exists in every radiological facility in Austria, the biomarker could be immediately deployed countrywide.
Wilder brings deep expertise in Image Guided Therapy to help accelerate commercialization and market expansion effortsCARLSBAD, Calif., March 02, 2021 (GLOBE NEWSWIRE) Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the appointment of Duane Wilder as the company’s Chief Commercial Officer. Mr. Wilder joins Acutus with over 25 years of commercial experience in the medical technology industry. Most recently, Mr. Wilder served as Vice President of US Sales, for the Image Guided Therapy division of Philips, where he had National responsibility for all of Philips’ Image Guided Therapy equipment and service sales, as well as the disposable catheters used with the equipment. Previously, Mr. Wilder held roles of increasing responsibility at Volcano Corp. (prior to its acquisition by Philips) since 2002, culminating in his role as Senior Vice President, U.S. Commercial, wh
Magnetic Resonance Imaging (MRI) is an accurate technique for detecting and classifying tumours in breast tissue. However, it sometimes causes false alarms , thus requiring further investigation (biopsy) and in some cases even resulting in so-called overtreatment, that is to say unnecessary surgery. For the first time, a research team from MedUni Vienna has now confirmed a threshold value for a non-invasive imaging biomarker. This can be incorporated into short standard MRI scans and could reduce the biopsy rate following MRI scans by 30%.
(2)
January 25, 2021
Two major randomized controlled trials (RCTs) show no difference in mortality between patients treated with the Philips Stellarex drug-coated balloon (DCB) and those treated with percutaneous angioplasty (PTA), the current standard of care
Amsterdam, the Netherlands -
Royal Philips).
The ILLUMENATE EU RCT and ILLUMENATE Pivotal RCT together comprised approximately 600 patients in Europe and the U.S. After five years, the ILLUMENATE EU RCT showed 19.3% mortality among patients treated with the Stellarex DCB compared to 19.4% mortality for those treated with PTA. The five-year results for the ILLUMENATE Pivotal study also show no statistically significant difference among patients treated with the Stellarex DCB (21.2%) compared to those treated with PTA (20.2%). Both studies had a high vital status follow-up compliance, with the status of over 90% of patients known.